Regulus Reports Second Quarter 2017 Financial Results and Recent Events
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/11/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
- AppLovin gains market share among e-commerce advertisers
Regulus Therapeutics (RGLS) Misses Q2 EPS by 8c
August 1, 2017 4:38 PM EDTRegulus Therapeutics (NASDAQ: RGLS) reported Q2 EPS of ($0.41), $0.08 worse than the analyst estimate of ($0.33).
For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.
... More